Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kissei's KUC-7483 Fails to Meet Efficacy Endpoint
July 12, 2010
- ASKA's Mid-Term Management Plan Calls For ¥48 Bil. Sales in FY2012
July 12, 2010
- Pariet Approved for Non-Erosive GERD in Japan: Eisai
July 12, 2010
- ASP1941 Fund to Reduce HbA1c in Japanese Patients in PII: Astellas
July 12, 2010
- Nippon Kayaku Aims at Doubling Pharma Sales to ¥100 Bil. in FY2015
July 12, 2010
- Janssen Applies for Golimumab for RA
July 12, 2010
- Omnaris HFA Meets Primary Endpoint for Efficacy in PIII: DSP
July 12, 2010
- AZ to Expand Production Capacity at Its Maibara Plant
July 12, 2010
- Banyu Applies for Vorinostat for CTCL in Japan
July 12, 2010
- Hematide Shows Non-Inferiority in 4 PIII Trials Overseas: Takeda, Affymax
July 12, 2010
- Korosho to Cancel 30% of Anti-Flu Vaccines from Novartis
July 12, 2010
- Joint Application Submitted for Acetaminophen Dosage Increase
July 12, 2010
- NDA for Anti-CCR4 Antibody to Be Filed Soon: Prof. Ueda
July 12, 2010
- Takeda Appoints Haruhiko Hirate as Corporate Officer
July 12, 2010
- Feraheme Applied for Iron Deficiency Anemia in Europe: Takeda
July 12, 2010
- Interim Analysis of PMS Data Confirms Favorable Safety Profile for Nexavar
July 12, 2010
- NanoCarrier Obtains Patent Related to Polymeric Micelles in Europe
July 12, 2010
- ZERIA to File NDA for Acotiamide in Japan This Fall
July 12, 2010
- Low-Dose SU Effective for Controlling Blood Glucose: JADEC Study
July 12, 2010
- Banyu, Schering-Plough Reorganize Sales, Marketing Structures
July 12, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…